Background: Psoriasis of the scalp is a very common disease, cosmetically disturbing and therapeutically difficult to manage. Objective: The aim of our study was to investigate the efficacy, safety and cosmetic acceptance of calcipotriol solution in a large number of patients with mild to moderate scalp psoriasis and to compare this treatment with previous therapies used. Methods: In this multicentre prospective observational cohort study 3,396 patients were treated with calcipotriol solution (50 µg/ml) twice daily over an 8-week period either alone or in combination with other treatments. The psoriasis scalp severity index (PSSI) and investigator/patient global assessment were used for the evaluation of clinical response. Results: All psoriasis severity parameters measured were reduced with a significant decrease in PSSI scores from 18.4 to 5.6 after 8 weeks of therapy (p < 0.001). About 80% of the patients showed very good or good clinical improvement. Combination of calcipotriol solution with other treatment modalities e.g. corticosteroids or salicylic acid, showed an increased treatment response. In only 2.4% of the patients side effects occurred (e.g. irritation). Conclusion: Calcipotriol solution is an effective, safe, well-tolerated and cosmetically acceptable treatment modality. By patients and physicians, this treatment was found to be a valuable supplement to previously available and established treatments for scalp psoriasis.

1.
Dawber R: Diseases involving the scalp; in Rook A, Dawber R (eds): Diseases of the Hair and Scalp. Oxford, Blackwell Scientific Publications, 1991, pp 506–509.
2.
Brun P: Psoriasis of the scalp; in Dubertret L (ed): Psoriasis. Brescia, ISED, 1994, pp 217–219.
3.
Kragballe K, Wildafang IL: Calcipotriol (MC903), a novel vitamin D3 analogue stimulates terminal differentiation and inhibits proliferation of cultured human keratinocytes. Arch Dermatol Res 1990;282:164–167.
4.
Glade CP, Van Erp PEJ, Boezeman JBM, Van de Kerkhof PCM: Multiparameter flow cytometry as a tool to evaluate antipsoriatic therapy. Br J Dermatol 1997;137:367–375.
5.
Binderup L, Bramm E: Effects of a novel vitamin D analogue MC903 on cell proliferation and differentiation in vitro on calcium metabolism in vivo. Biochem Pharmacol 1988;37:889–895.
6.
Kragballe K: Treatment of psoriasis by the topical application of the novel cholecalciferol analogue calcipotriol (MC 903). Arch Dermatol 1989;125:1647–1652.
7.
Dubertret L, Wallach D, Souteyrand P, et al: Efficacy and safety of calcipotriol (MC 903) ointment in psoriasis vulgaris: A randomised, double-blind, right/left comparative, vehicle-controlled study. J Am Acad Dermatol 1992;27:983–988.
8.
Ramsay CA, Berth-Jones J, Brundin G, et al: Long-term use of topical calcipotriol in chronic plaque psoriasis. Dermatology 1994;189:260–264.
9.
Bleiker TO, Bourke JF, Mumford R, Hutchinson PE: Long-term outcome of severe chronic plaque psoriasis following treatment with high-dose topical calcipotriol. Br J Dermatol 1998;139:285–286.
10.
Kragballe K, Barnes L, Hamber KJ, et al: Calcipotriol cream with or without concurrent topical corticosteroids in psoriasis: Tolerability and efficacy. Br J Dermatol 1998;139:649–654.
11.
Harrington CI, Goldin D, Lovell CR, et al: Comparative effects of two different calcipotriol (MC903) cream formulations versus placebo in psoriasis vulgaris: A randomized double-blind, placebo-controlled, parallel group multi-centre study. J Eur Acad Dermatol Venereol 1996;6:152–158.
12.
Green C, Ganpule M, Harris D, et al: Comparative effects of calcipotriol (MC903) solution and placebo (vehicle of MC903) in the treatment of psoriasis of the scalp. Br J Dermatol 1994;130:483–487.
13.
Klaber MR, Hutchinson PE, Pedvis-Leftick A, et al: Comparative effects of calcipotriol solution (50 μg/ml) and betamethasone 17-valerate solution (1 mg/ml) in the treatment of the scalp psoriasis. Br J Dermatol 1994;131:678–683.
14.
Lebwohl M: Topical application of calcipotriene and corticosteroids: Combination regimens. J Am Acad Dermatol 1997;37:55–58.
15.
Katz ICH: Combined topical calcipotriene ointment 0.005% and various systemic therapies in the treatment of plaque-type psoriasis vulgaris: Review of the literature and results of a survey sent to 100 dermatologists. J Am Acad Dermatol 1997;37:62–68.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.